
A multicenter study found that immune-related adverse events (irAEs) in advanced melanoma patients treated with ICIs are associated with improved survival. However, early and high-dose corticosteroid use may negatively impact outcomes, underscoring the importance of tailored immunosuppression strategies.
Like
Save
Share